C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value
$2.76−0.01 (-0.36%)
Close on Nov 13, 2026Market cap $339.55MP/E –Yield –
C4 Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
C4 Therapeutics's price to sales ratio was 10.1× on Nov 11, 2026, against 6.7× a year earlier. Over the last 5 years it ranged from 2.2× to 32.0×, with a median of 8.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.1× | +5.4 |
| 2025 | Dec 31, 2025 | 4.7× | −2.8 |
| 2024 | Dec 31, 2024 | 7.5× | −6.1 |
| 2023 | Dec 29, 2023 | 13.7× | +7.7 |
| 2022 | Dec 30, 2022 | 6.0× | – |
See a number that looks wrong?